PICO Portalanswers from OpenAlex
US Biologic (United States)
InstitutionResearch output, impact & collaborations
US Biologic (United States) is a institution indexed in PICO Portal from OpenAlex.
What is known about US Biologic (United States)?
PICO Portalrecord summary
US Biologic (United States) is a research organisation in Memphis, US. OpenAlex records 1,470 works and 57,568 citations for it. 634 researchers list it as their most recent affiliation.
How many works does US Biologic (United States) have?
PICO Portalindexed works
US Biologic (United States) has 1,470 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does US Biologic (United States) have?
PICO Portalcitation count
US Biologic (United States) has 57,568 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at US Biologic (United States)?
PICO Portalresearcher count
US Biologic (United States) has 634 researchers in the PICO Portal index.
What is the average h-index at US Biologic (United States)?
PICO Portalavg h-index
US Biologic (United States) has an average h-index of 22 in OpenAlex.
What is the ROR of US Biologic (United States)?
PICO Portalror
The ROR for US Biologic (United States) is on the source record.
What is the OpenAlex record for US Biologic (United States)?
PICO Portalopenalex
The OpenAlex for US Biologic (United States) is on the source record.
Who are the most-cited researchers behind US Biologic (United States)?
PICO Portaltop researchers by citations
What are the most-cited papers on US Biologic (United States)?
PICO Portalmost cited works
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
Combined MTOR and autophagy inhibition
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M. Algazy, Tracey L. Evans, Leslie A. Fecher, Lynn M. Schuchter, Drew A. Torigian, Jeffrey T Panosian, Andrea B. Troxel, Kay-See Tan, Daniel F. Heitjan, Angela DeMichele, David J. Vaughn, Maryann Redlinger, Abass Alavi, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Peter J. O’Dwyer, Ravi K. Amaravadi
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma Rangwala, Robert D. Leone, Yunyoung C Chang, Leslie A. Fecher, Lynn M. Schuchter, Amy Kramer, Kay-See Tan, Daniel F. Heitjan, Glenda Rodgers, Maryann Gallagher, Shengfu Piao, Andrea B. Troxel, Tracey L. Evans, Angela DeMichele, Katherine L. Nathanson, Peter J. O’Dwyer, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Ravi K. Amaravadi
How much of the research on US Biologic (United States) is open access?
PICO Portalopen access share
80%OPEN ACCESS